NCT00614393-open-paren-b-close-paren-_3A: NCT00614393(b), figure 3A

NCT00614393(b)_3AR Documentation

NCT00614393(b), figure 3A

Description

Kaplan-Meier digitized data from NCT00614393(b), figure 3A (PMID 26405092). A reported sample size of 344 for a primary endpoint of PFS,OS in colorectal cancer.

Usage

`NCT00614393(b)_3A`

Format

A data frame of 228 observations and 3 variables:

time event time (in months)
event PFS event indicator (0: no event, 1: event)
arm treatment arms (armb, armc)

Source

Sclafani F, Kim TY, Cunningham D, et al. A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer. J Natl Cancer Inst 2015; 107: djv258.

Examples

summary(`NCT00614393(b)_3A`)

kmplot(`NCT00614393(b)_3A`)

raredd/kmdata documentation built on June 15, 2025, 9:33 a.m.